- Home
- SEVN vs CRDF Comparison
SEVN vs CRDF Comparison
Compare SEVN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- CRDF
- Stock Information
- Founded
- SEVN 1986
- CRDF 1999
- Country
- SEVN United States
- CRDF United States
- Employees
- SEVN N/A
- CRDF N/A
- Industry
- SEVN Real Estate Investment Trusts
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEVN Real Estate
- CRDF Health Care
- Exchange
- SEVN Nasdaq
- CRDF Nasdaq
- Market Cap
- SEVN 149.0M
- CRDF 152.3M
- IPO Year
- SEVN N/A
- CRDF N/A
- Fundamental
- Price
- SEVN $9.46
- CRDF $2.35
- Analyst Decision
- SEVN Strong Buy
- CRDF Strong Buy
- Analyst Count
- SEVN 2
- CRDF 5
- Target Price
- SEVN $13.50
- CRDF $11.10
- AVG Volume (30 Days)
- SEVN 122.0K
- CRDF 839.6K
- Earning Date
- SEVN 10-27-2025
- CRDF 10-29-2025
- Dividend Yield
- SEVN 11.84%
- CRDF N/A
- EPS Growth
- SEVN N/A
- CRDF N/A
- EPS
- SEVN 1.04
- CRDF N/A
- Revenue
- SEVN $29,408,000.00
- CRDF $545,000.00
- Revenue This Year
- SEVN N/A
- CRDF N/A
- Revenue Next Year
- SEVN N/A
- CRDF N/A
- P/E Ratio
- SEVN $9.12
- CRDF N/A
- Revenue Growth
- SEVN N/A
- CRDF N/A
- 52 Week Low
- SEVN $9.22
- CRDF $1.90
- 52 Week High
- SEVN $13.97
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- SEVN 33.22
- CRDF 56.18
- Support Level
- SEVN $9.23
- CRDF $2.10
- Resistance Level
- SEVN $10.90
- CRDF $2.38
- Average True Range (ATR)
- SEVN 0.29
- CRDF 0.11
- MACD
- SEVN -0.10
- CRDF 0.01
- Stochastic Oscillator
- SEVN 13.77
- CRDF 69.44
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.